Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Reply Letter titled “Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan—Reply,”1 published online March 22, 2017, and in the July 2017 issue of JAMA Cardiology, the author disclosed conflicts of interest that were inadvertently omitted. The Conflict of Interest Disclosures section should read as follows: “The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Packer has received personal fees from Amgen, Admittance, Bayer, Boehringer Ingelheim, Celyad, Daiichi Sankyo, Ferring, GlaxoSmithKline, Novartis, Relypsa, Sanofi, Takeda, and ZS Pharma.” This article was corrected online.
Omitted Conflict of Interest Disclosures. JAMA Cardiol. 2018;3(3):266. doi:10.1001/jamacardio.2017.5142
Cardiology in JAMA: Read the Latest